USD 2.3 billion
Report ID:
SQMIG35G2123 |
Region:
Global |
Published Date: March, 2025
Pages:
219
|Tables:
62
|Figures:
78
Contrast Enhanced Mammography Market size was valued at USD 2.3 billion in 2023 and is poised to grow from USD 2.44 billion in 2024 to USD 3.89 billion by 2032, growing at a CAGR of 6.0% during the forecast period (2025-2032).
Using a dual-energy technique, contrast-enhanced mammography (CEM) combines the benefits of digital mammography with intravenous contrast. CEM is more sensitive than full-field digital mammography (FFDM) alone and FFDM combined with ultrasound for detecting breast cancer in the diagnostic setting.
Due to the rising prevalence of breast cancer worldwide, Contrast Enhanced Mammography (CEM) has become a highly popular and most commonly used technique. Factors that increase the risk of breast cancer include age, obesity, harmful alcohol use, family history of breast cancer, radiation exposure history, reproductive history (age at first menstrual cycle and first pregnancy), tobacco use, and postmenopausal hormone therapy. Majority of breast cancer cases occur in females, affecting a large proportion of the population. It is mostly found in the breast tissues that breast cancer develops. There are several symptoms of breast cancer, such as lumps in the breast, changes in the size and shape of the breast, fluid coming out of the nipple, and itchiness, scaliness, and redness on the skin. In addition to pain in the bones, swelling of lymph nodes, breathing problems, and other symptoms, this disorder causes the disease to spread. As a result, breast cancer prevalence is on the rise throughout the world, driving market growth.
US Contrast Enhanced Mammography Market is poised to grow at a sustainable CAGR for the next forecast year.
Market snapshot - 2025-2032
Global Market Size
USD 2.3 billion
Largest Segment
Hospital
Fastest Growth
Hospital
Growth Rate
6.0% CAGR
To get more reports on the above market click here to Buy The Report
Global Contrast Enhanced Mammography Market is segmented by Applications, End User and region. Based on Applications, the market is segmented into Screening and Diagnosis. Based on End User, the market is segmented into Hospital, Diagnostic Centres, Specialty Clinics and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
The hospitals segment dominated the global market in 2022. As patients are hospitalized more frequently and the disease burden increases, the segment is expected to grow. Additionally, PET, CT, and MRI are used to monitor disease progression and assess the effectiveness of cancer treatments. However, due to the increasing number of initiatives undertaken by governments to provide various services, such as reimbursement for diagnostic tests, the segment of diagnostic centers is expected to grow significantly over the forecast period.
To get detailed analysis on other segments, Request For Free Sample Report
The North America region is anticipated to dominate the global contrast enhanced mammography market. The presence of large players, established diagnostic and screening infrastructure, technological breakthroughs, high patient awareness, and reimbursement regulations are the main drivers of this region's dominance.
Due to the rising incidence of breast cancer and the adoption of cutting-edge diagnostic methods, the market in Asia Pacific region is anticipated to experience the greatest CAGR over the forecast period. Additionally, it is anticipated that expanding healthcare infrastructure and bettering reimbursement policies will promote market growth.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Request Free Customization of this report to help us to meet your business objectives.
Some of the major players engaged in the market are Hologic, Inc., GE Healthcare, Siemens Healthineers, Fujifilm Medical Systems, Planmed Oy. Other players include, Metaltronica, Carestream Health, and General Medical Merate. The market is also experiencing the entry of new players, which is expected to intensify competition in the coming years.
SkyQuest's ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Co-relates and Analyses the Data collected by means of Primary Exploratory Research backed by the robust Secondary Desk research.
According to our global contrast enhanced mammography market analysis, rising prevalence of breast cancer across the globe, increasing approvals for new technologies, surging investments by government as well as major key players are driving market growth.
Report Metric | Details |
---|---|
Market size value in 2023 | USD 2.3 billion |
Market size value in 2032 | USD 3.89 billion |
Growth Rate | 6.0% |
Base year | 2024 |
Forecast period | 2025-2032 |
Forecast Unit (Value) | USD Billion |
Segments covered |
|
Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
Companies covered |
|
Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Contrast Enhanced Mammography Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Contrast Enhanced Mammography Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Contrast Enhanced Mammography Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Contrast Enhanced Mammography Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
Contrast Enhanced Mammography Market size was valued at USD 1.94 Billion in 2023 and is poised to grow from USD 2.04 Billion in 2024 to USD 3.07 Billion by 2032, growing at a CAGR of 5.28% during the forecast period (2025-2032).
Some of the major players engaged in the market are Hologic, Inc., GE Healthcare, Siemens Healthineers, Fujifilm Medical Systems, Planmed Oy. Other players include, Metaltronica, Carestream Health, and General Medical Merate. The market is also experiencing the entry of new players, which is expected to intensify competition in the coming years. 'Hologic Inc.', 'GE Healthcare', 'Siemens Healthineers AG', 'Koninklijke Philips N.V.', 'Fujifilm Holdings Corporation', 'Dilon Technologies Inc.', 'Planmed Oy', 'Metaltronica S.p.A.', 'CMR Naviscan Corporation', 'General Medical Merate S.p.A.', 'Delphinus Medical Technologies Inc.', 'Micrima Limited', 'KUB Technologies Inc.', 'Aurora Imaging Technology Inc.', 'Carestream Health Inc.', 'Planmed Oy', 'Zebra Medical Vision Ltd.', 'Volpara Health Technologies Ltd.', 'iCAD Inc.', 'Agfa-Gevaert NV', 'In October 2023, Hologic and Bayer announced a collaborative effort to advance contrast-enhanced mammography (CEM) adoption across Asia Pacific, Canada, and Europe. This pioneering technique involves administering iodinated contrast intravenously and utilizing both low-energy and high-energy X-rays, akin to digital mammography. The iodine selectively absorbs high-energy X-rays, potentially improving cancer detection accuracy. ', 'In October 2023, Syracuse became the hub for cutting-edge breast cancer imaging technology with the installation of two 3-D mammography units at Crouse Hospital. This state-of-the-art technology aims to detect cancerous tumors at earlier stages and enhance cancer detection in denser breast tissue. ', 'In June 2023, Bayer announced that its iodine-based contrast agent, Ultravist (iopromide)-300, -370, received approval from the U.S. Food and Drug Administration (FDA) for contrast-enhanced mammography (CEM). This approval makes Ultravist the only contrast agent authorized for this specific indication. The product is intended for visualizing known or suspected breast lesions in adults, serving as an adjunct to mammography and/or ultrasound. CEM is an emerging imaging modality that combines digital mammography with the administration of a contrast agent like Ultravist to aid in the identification of breast lesions. '
The major factor driving the market growth is rising incidence of breast cancer. Breast cancer is the most common cancer among women worldwide. It is possible to treat breast cancer extremely effectively, especially if the disease is diagnosed early. A breast cancer patient is generally treated with surgery, radiation therapy, and medications (hormone therapy, chemotherapy, and/or targeted biological therapy) to treat the microscopic cancer that has spread from the breast tumor. Treatments such as these can prevent cancer growth and spread, thereby saving lives.
Every year, the incidence of breast cancer in women rises, along with the market expansion and the number of treatments available. Enhanced techniques for breast cancer diagnostics using advanced technologies. More sophisticated technologies for the early detection of breast cancer have improved performance in terms of efficiency, accuracy, efficacy, dependability, and speed of results.
The North America region is anticipated to dominate the global contrast enhanced mammography market. The presence of large players, established diagnostic and screening infrastructure, technological breakthroughs, high patient awareness, and reimbursement regulations are the main drivers of this region's dominance.
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
Report ID: SQMIG35G2123
[email protected]
USA +1 351-333-4748